Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in MRT over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.This piece reflects my honest market outl ...

Marti Technologies, Inc. (NYSE: MRT ) is at an exciting inflection point, with the potential to lead the emerging ride-hailing market in Turkey. It has capitalized on its leading micromobility, including its ride-sharing position and a two-year investment to build a scaledYiannis Zourmpanos, founder of Yiazou IQ, an AI-driven stock research platform providing all-in-one stock reports. Experience: Previously worked at Deloitte and KPMG in external/internal auditing and consulting. Education: Chartered Certif ...

Results from dose escalation arms of Phase 1/2 study of MRT-2359 demonstrated a favorable safety profile and targeted levels of GSPT1 degradation using a 21 days on, 7 days off drug dosing schedule in heavily pretreated solid tumor patients Recommended Phase 2 dose determined as 0.5 mg daily at a 21 days on, 7 days off drug dosing schedule Additional MRT-2359 Phase 1/2 study clinical results, including biomarker and activity data, anticipated in Q1 2025 BOSTON, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Monte Rosa T ...

SINGAPORE, Nov. 22, 2024 (GLOBE NEWSWIRE) -- SIMPPLE Ltd. (NASDAQ: SPPL) (“SIMPPLE” or “the Company”), a leading technology provider and innovator in the facilities management sector, through its subsidiary, today announced that the Company had completed the sale and successful deployment of 89 autonomous cleaning robots across Singapore, marking the largest robotic fleet in the land transport sector with rail operator SMRT Trains. Aligned with the broader Singapore Government initiative to push towards gr ...

Singapore, Nov. 22, 2024 (GLOBE NEWSWIRE) -- SIMPPLE Ltd. (NASDAQ: SPPL) (“SIMPPLE” or “the Company”), a leading technology provider and innovator in the facilities management sector, through its subsidiary, today announced that the Company had completed the sale and successful deployment of 89 autonomous cleaning robots across Singapore, marking the largest robotic fleet in the land transport sector with rail operator SMRT Trains. Aligned with the broader Singapore Government initiative to push towards gr ...

Marti Technologies, Inc. (NYSE:MRT) Q2 2024 Earnings Conference Call September 30, 2024 8:30 AM ET Company Participants Oguz Alper Oktem - Founder and Chief Executive Officer Cankut Durgun - Co-Founder and President Conference Call Participants Brett Knoblauch - Cantor Fitzgerald Poe Fratt from - Global Partners Operator Hello, everyone, and thank you for joining us for Marti's First Half 2024 Conference Call. Before we begin, I'd like to mention that today's presentation and earnings release are available ...

MRT-6160, a potent and highly selective VAV1-directed molecular glue degrader, represents a potential novel therapeutic approach for systemic and neurological autoimmune and inflammatory diseases Initial Phase 1 clinical results, including biomarker data to demonstrate pharmacodynamic effects, anticipated in Q1 2025 BOSTON, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, tod ...

About Monte Rosa Poster presentation today at 14:45 CET / 8:45 a.m. ET Summary of findings: The poster, entitled "MRT-6160, a VAV1-Directed Molecular Glue Degrader, Reduces Joint Inflammation and Autoantibody Production in a Collagen-Induced Arthritis Autoimmune Disease Model" (Poster Number 1200), will be presented today by Adam Cartwright, Ph.D., Senior Scientist II at Monte Rosa Therapeutics, at 14:45 CET / 8:45 a.m. ET. Initiation of MRT-6160 Phase 1 SAD/MAD study anticipated in mid-year 2024 with initi ...

MRT-6160, a VAV1-directed molecular glue degrader (MGD), inhibits colitis disease progression and colon inflammation, lowers inflammatory mucosal cytokines, and reduces expression of IBD-associated genes in a colitis model Initiation of MRT-6160 Phase 1 SAD/MAD study anticipated in mid-year 2024 with Phase 1 clinical data expected in Q1 2025 Poster presentation today at 12:30 pm ET BOSTON, May 21, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical- stage biotechnology company ...

Marti Technologies, Inc. (NYSE:MRT) Q4 2023 Earnings Call Transcript April 16, 2024 8:30 AM ET Company Participants Oguz Alper Oktem - Founder and CEO Cankut Durgun - Co-Founder and President Conference Call Participants Thomas Shemia - Cantor Fitzgerald Operator Hello, everyone, and thank you for joining us for Marti's Full Year 2023 Conference Call. Before we begin, I would like to mention that today's presentation and earnings release are available on Marti's investor relations website at ir.marti.tech, ...